Se

## Contains No CBI



93 SEP 14 PH 2: 15

INTERNATIONAL INSTITUTE OF SYNTHETIC RUBBER PRODUCERS, INC.

8EHQ - 0993-12435

13 September 1993

Document Processing Center
Attn: TSCA 8 (e) Coordinator
Chemical Information Division
Office of Toxic Substances
U.S. Environmental Protection Agency
401 M. Street, S.W.
Washington, D.C. 20460

Re: TSCA 8(e) Submittal





8893000045


Dear Sir:

The International Institute of Synthetic Rubber Producers, Inc. (hereinafter, "IISRP") is submitting this notice pursuant to Section 8(e) of the Toxic Substances Control Act (TSCA). This information is not confidential.

This TSCA 8(e) submission is made on behalf of the companies who are parties to the isoprene research being carried out at Battelle laboratories under sponsorship of the IISRP. These companies are: Chevron Chemical Company, Dow Chemical USA, EniChem Elastomeri SrL, Exxon Chemical Company, Goodyear Tire & Rubber Company, Polysar Rubber Corporation, Shell Chemical Company, and Shell International Chemical Co. Ltd.

This submittal relates to isoprene (CAS #78-79-5). A chronic inhalation oncogenicity study in B6C3F1 mice with isoprene is ongoing at Battelle laboratories in Columbus, Ohio. This study is sponsored by the IISRP. Prior related reports have been submitted to EPA under Section 8(e) by Chevron Chemical Company (see letter from John C. Litterio, February 3, 1993) and Shell Oil Company, (see letter from Roy D. Gerard, June 10, 1992).

The exposure and experimental design, which is summarized below, were intended to assess the effects of concentration, length of daily exposure, and duration of total exposure over the lifespan of the animals, as independent variables of the survival and ultimate oncogenicity of the test article.



## CHRONIC INHALATION STUDY OF ISOPRENE IN MICE Experimental Design

Test Article Concentration, ppm	Daily Exposure Hours	Numbers of Weeks Exposed	Number of Mice B6C3F <sub>1</sub>
0	8	80	50M, 50F
10	8	80	50M, 50F
70	8	40	50M
70	8	80	50M, 50F
140	8	40	50M
280	8	20	50M
280	8	80	50M
700	8	80	50M
2200	4	20	50M
2200	4	80	50M
2200	8	40	50M
2200	8	80	50M

The in-life phase of this study ended in April of 1993. The total set of tissues from this study have not been fully evaluated or peer-reviewed, nor have final biostatistics been completed. Nonetheless, in a preliminary assessment of the histopathology and other post mortem data there appears to be an increased incidence of hemangiosarcomas and histiocytic sarcomas, and possibly lymphomas, tumor types not reported in the NTP inhalation study of isoprene in mice. In addition, the results of this study appear to confirm the exposure-related incidence of liver, lung, Harderian gland and forestomach tumors reported in the NTP study.

In addition to the above observations, cytogenetic experiments included as part of this study indicated a concentration-dependent increase in the incidence of micronuclei in exposed mice. When compared to controls and to those animals exposed to lower concentrations of isoprene, the percent increase in micronuclei persent in peripheral blood appeared to increase in animals exposed to concentrations of 280 ppm or greater for 80 weeks. Further, there appeared to be an exposure-related decrease in ovarian weights of female mice exposed to concentrations of 70 ppm of isoprene for 80 weeks compared to control mice. There may be an exposure related decrease in testicular weights at ≥700 ppm. Lastly, to confirm data previously reported to the Agency, the survival rates were lower in mice exposed to isoprene concentrations of 280 ppm and above for periods of 80 weeks. There were no apparent exposure-related effects on growth rate or the clinical condition of the animals.

We stress that these conclusions are preliminary and that statistical analyses are ongoing. The final report for the IISRP-sponsored isoprene study will be submitted when available. If you have any questions, please contact Michael G. Bird, Ph.D., Exxon Biomedical Sciences, Inc., Mettlers Road, CN 2350, East Millstone, New Jersey 08875-2350 (telephone 908/873 6067).

Sincerely,

William E. Tessmer
Managing Director

File ISO(E).VAR



## UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

William E. Tessner Managing Director International Institute of Synthetic Rubber Producers, Inc. 2077 South Gessner Road, Suite 133 Houston, Texas 77063

PESTICIDES AND TOXIC SUBSTANCES

JAN 2 5 1994

This letter formally acknowledges EPA's receipt of information submitted by your organization under Section 8(e), the "substantial risk" information reporting provision of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA Section 8(e) Document Control Number (i.e., 8EHQ-0000-0000 Init.) assigned by EPA to your submission(s). Please refer to this cited number when submitting follow-up or supplemental information.

Please note that all submitted correspondence will be placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA Section 8(e) policy statement (43 FR 11110, March 16, 1978).

Confidential submissions submitted pursuant to the TSCA Section 8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims, because substantiation of CBI claims is required at the same time the 8(e) CAP is submitted to EPA. (If not done so already, please ensure that this information is provided to the Agency). When substantiating any/all claims, answer the questions detailed in the following attachment.

For NON-CAP submissions, any confidentiality claims should be supported by submission of information as described in the attachment(s).

12435 A

## Triage of 8(e) Submissions

Date sent to triage: JAN 2 8 1994	NON-CAP	CAP	
Submission number: 12435A	TSCA Inventory:	Y N	D
Study type (circle appropriate):			
Group 1 - Dick Clements (1 copy total)			
ECO AQUATO			
Group 2 - Erne Falke (1 copy total)			
ATOX SBTOX SEN w/NEU	R		
Group 3 - Elizabeth Margosches (1 copy each)			
STOX CTOX/ONCO CTOX RTOX	GTOX		
NEUR EPI IMMUNO CYTO	XX.		
Other (FATE, EXPO, MET, etc.):  Notes:			
For Contractor Use Only entire document: 1 2 3 pages 1-3  Notes:  Contractor reviewer: DMC	pages <u>1-3</u>		
Date	1/12/94		

VOLUNTARY ACTIONS:  OOD FOO ACTION REPORTED OOD STUDIES PLANNEDAINDERWAY OOD NOTIFICATION OF WORKE.HAD THE NALE) OOD PROCESSHANDLING CHANGES OOD PROCESSHANDLING OF WORKER OOD PRODUCTION DISCONTINUED OOD CONFIDENTIAL	NEORMANION INCE.   P. F. C.
INFORMATION REQUESTED: FLWP DATE  9501 INFO REQUESTED  9502 INFO REQUESTED (TECH)  9503 INFO REQUESTED (TECH)  9504 INFO REQUESTED (TECH)  9504 INFO REQUESTED (TECH)  9504 INFO REQUESTED (TECH)  9505 INFO REGUESTED (TECH)  9505 INFO REQUESTED (TECH)  9505 INFO REGUESTED (TECH)  950	HECREACTION TITE:  216 EPVCLIN  217 HUMAN EXPOS (PROD CONTAN)  218 HUMAN EXPOS (ACCEDENTAL)  219 HUMAN EXPOS (ACCEDENTAL)  220 EMEN EXPOS (ACCEDENTAL)  221 EMEN EXPOS (ACCEDENTAL)  222 EMEN EXPOS (ACCEDENTAL)  223 EMEN EXPOS (ACCEDENTAL)  224 EMEN EXPOS ENV CONTAN  225 EMEN EXPOS ENV CONTAN  226 CONFEDENTIAL  227 ALLERG (ANHAAL)  228 CONFEDENTIAL  228 CONFEDENTIAL  229 HECRE  230 ALLERG (ANHAAL)  240 HECRE  241 ALLERG (ANHAAL)  252 EMEN EXPOSE  253 CONFEDENTIAL  254 HECRE  255 ALLERG (ANHAAL)  256 HECRE  257 ALLERG (ANHAAL)  258 HECRE  259 METAMPHARIAMON (HUMAN)  250 HECRE  250 CONFEDENTIAL  250 HECRE  251 CONFEDENTIAL  251 HECRE  252 CONFEDENTIAL  253 HECRE  254 HECRE  255 CONFEDENTIAL  256 HECRE  257 ALLERG (ANHAAL)  258 HECRE  259 HECRE  250 HECR
seo A and a distribution of 1/4	P. F. C.  St. C.
HICATS DATA.  WHOMESTAND OF STATES SEO. A  VIEWITTER NAME IN LEWART. In. ST. OF  UIR DATE. OR IS STATES OF OTS DATE. OR  HEMICAL NAME.	NFORMATION TITE:  201 ONCO (HUMAN)  202 ONCO (NIBAAL)  203 CELL TRANS (N VITRO)  204 MUTA (N VITRO)  205 MUTA (N VITRO)  206 MUTA (N VITRO)  206 MUTA (N VITRO)  207 NEPROTIERATO (HUMAN)  208 NEURO (HUMAN)  210 ACUTE TOX (HUMAN)  211 ACUTE TOX (HUMAN)  212 ACUTE TOX (HUMAN)  213 SUB ACUTE TOX (ANBAL)  214 SUB ACUTE TOX (ANBAL)  215 SUB ACUTE TOX (ANBAL)  216 SUB ACUTE TOX (ANBAL)  217 SUB CHRONIC TOX (ANBAL)  218 SUB CHRONIC TOX (ANBAL)  219 SUB CHRONIC TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 SUB CHRONIC TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 SUB CHRONIC TOX (ANBAL)  214 SUB CHRONIC TOX (ANBAL)  215 SUB CHRONIC TOX (ANBAL)  216 SUB CHRONIC TOX (ANBAL)  217 SUB CHRONIC TOX (ANBAL)  218 ACUTE TOX (ANBAL)  219 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 ACUTE TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 SUB CHRONIC TOX (ANBAL)  214 SUB CHRONIC TOX (ANBAL)  215 ACUTE TOX (ANBAL)  216 ACUTE TOX (ANBAL)  217 ACUTE TOX (ANBAL)  218 ACUTE TOX (ANBAL)  219 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 ACUTE TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 ACUTE TOX (ANBAL)  214 ACUTE TOX (ANBAL)  215 ACUTE TOX (ANBAL)  216 ACUTE TOX (ANBAL)  217 ACUTE TOX (ANBAL)  218 ACUTE TOX (ANBAL)  219 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 ACUTE TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 ACUTE TOX (ANBAL)  214 ACUTE TOX (ANBAL)  215 ACUTE TOX (ANBAL)  216 ACUTE TOX (ANBAL)  217 ACUTE TOX (ANBAL)  218 ACUTE TOX (ANBAL)  219 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 ACUTE TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 ACUTE TOX (ANBAL)  214 ACUTE TOX (ANBAL)  215 ACUTE TOX (ANBAL)  216 ACUTE TOX (ANBAL)  217 ACUTE TOX (ANBAL)  218 ACUTE TOX (ANBAL)  219 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  210 ACUTE TOX (ANBAL)  211 ACUTE TOX (ANBAL)  212 ACUTE TOX (ANBAL)  213 ACUTE TOX (ANBAL)  ACUTE TOX (ANBAL)

12435 Isoprene

CONCERN: HIGH

A chronic inhalation study of isoprene was conducted in B6C3F1 mice at levels of 10, 70, 140, 280, 700, or 2200 ppm. Exposure was 8 hours a day for all groups except the highest which was also tested at 4 hours/day. Duration of exposure was 80 weeks at each exposure level. In addition, at 70 and 140 ppm a 40-week exposure duration and at 280 and 2200 ppm 20-week exposure durations were also tested.

Preliminary assessment of histopathology, indicated an apparent increase in hemangiosarcomas and histocytic sarcomas as well as an increase in lung, liver, Harderian gland and forestomach tumors.

5) 8EHQ-0993-612435 Init: Rank - medium.

Chemical: isoprene (CAS# 78-79-5).

Title of study, laboratory and date not given: Positive for chromosome mutations (micronuclei) in peripheral blood of mice exposed  $\underline{in}\ \underline{vivo}$ .